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Abstract
Background
Bone fragility is common post solid organ transplantation but little is known about bone
pathology on a tissue level. Abnormal osteocytic protein expression has been linked to com-
promised bone health in chronic kidney disease (CKD) and immunosuppressant medica-
tions may impact osteocyte function.
Methods
Transiliac bone biopsies were obtained from 22 pediatric solid organ allograft recipients
(average age 15.6 years) an average of 6.3 ± 1.2 years after transplantation and from 12
pediatric pre-dialysis CKD patients (average age 13.2 years). Histomorphometry and immu-
nohistochemistry for FGF23, DMP1, sclerostin, and osteopontin were performed on all
biopsies.
Results
FGF23 and sclerostin were increased in transplant recipients relative to non-transplant
CKD, regardless of the type of allograft received and despite, in the case of liver and heart
recipients, a higher GFR. Bone DMP1 expression was higher in liver or heart than in kidney
recipients, concomitant with higher serum phosphate values. Osteopontin expression was
higher in CKD than in transplant recipients (p<0.01). Bone FGF23 and sclerostin correlated
directly (r = 0.38, p<0.05); bone FGF23 expression and osteoid thickness correlated
inversely (r = - 0.46, p<0.01).
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Conclusions
Solid-organ transplantation is associated with increased FGF23 and sclerostin expression.
The contribution of these findings to compromised bone health post transplantation war-
rants further evaluation.
Introduction
Skeletal problems are common in pediatric recipients of solid organ allografts, with fractures in
general occurring 6 times as commonly as in the general population and vertebral fractures,
specifically, occurring at even higher rates [1,2]. While the deleterious effects of immunosup-
pressive agents contribute to skeletal morbidity in all allograft recipients, the residual effects of
renal osteodystrophy, which is associated with bone fragility and skeletal deformities in chil-
dren with chronic kidney disease (CKD) [3,4], may also contribute to skeletal morbidity post-
renal transplantation.
Osteocytes are key regulators of bone modeling and remodeling [5] and current data suggest
that CKD is associated with abnormal expression of different osteocytic proteins [6,7], some of
which, such as fibroblast growth factor 23 (FGF23) and dentin matrix protein 1 (DMP1), play
a role in regulating skeletal mineralization and others of which (namely sclerostin) regulate
osteoblast differentiation [5,8]. Abnormalities in osteocytic protein expression occur in early
CKD, before abnormalities in mineral ion, vitamin D, and parathyroid hormone (PTH) con-
centrations are apparent and coincide with early changes in bone turnover and mineralization
[6,7]. Some data also suggest that circulating FGF23 levels are affected by immunosuppressant
medications [9]; however, the effects of immunosuppressant agents and their interaction with
decreased renal function on osteocytic protein expression have not been evaluated. Thus, in
order to gain more knowledge on the pathological processes contributing to skeletal fragility
after pediatric solid organ transplantation, in which the presence of CKD and the use of immu-
nosuppressant agents may both contribute to skeletal pathology, we evaluated osteocytic pro-
tein expression and bone histology in a cohort of kidney, liver, and heart transplant recipients
and in subjects with pre-dialysis CKD.
Methods
Patients
This cross-sectional analysis represents data from two institutions. Transiliac bone biopsies
from pediatric kidney, liver, and heart transplant recipients were obtained from 22 children
(mean age: 15.6 years; age range: 7.6 to 19.8 years) with a history of kidney (n = 8), liver
(n = 9), or heart (n = 5) transplantation as a part of clinical evaluation for suspected osteoporo-
sis at the Children’s Hospital, Helsinki University Central Hospital, where all pediatric solid
organ transplantations and post-operative care are centralized in Finland. Study participants
were, on average, 9.4 ± 1.2 years of age at the time of transplantation and bone biopsies were
performed 6.3 ± 1.2 years post transplantation. The bone histomorphometric, biochemical,
and bone density data from a subset of 19 of these individuals have been previously reported
[10]; the current study presents these individuals as well as 3 additional (2 kidney and 1 heart)
transplant recipients who subsequently underwent bone biopsy. Bone biopsies from 12 pre-dial-
ysis CKD patients (mean age: 13.2 years; age range: 2.2 to 19.8 years) were obtained at UCLA
as part of a previously reported study characterizing the spectrum of renal osteodystrophy in
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pediatric pre-dialysis CKD [11]. This study was approved by the both the UCLA and the Uni-
versity of Helsinki institutional review boards. Due to the use of de-identified historical samples,
informed consent was waived by both institutions.
All solid organ transplant recipients had received glucocorticoids since transplantation and
were receiving low-dose alternate-day oral glucocorticoids (methylprednisolone). Total cumu-
lative (mg) and weight-adjusted (mg/kg) glucocorticoid doses as well as glucocorticoid expo-
sure (mg/kg/days) during the previous 3 years were calculated [10]. None of the children had
been treated with aluminum-containing phosphate binders or bisphosphonates. None of the
patients had received growth hormone treatment.
Bone Biopsy and Histomorphometry
Full thickness bone biopsies were obtained from the anterior iliac crest using a modified Bor-
dier trephine (0.5 cm diameter) needle after double tetracycline-labeling. Specimens were fixed
in 70% ethanol, dehydrated in alcohol, cleared with xylene, and embedded in methylmethacry-
late. Static histomorphometric parameters were evaluated in undecalcified 5 μm sections
stained with Toluidine blue; tetracycline labeling was assessed in unstained 10 μm sections.
Primary bone histomorphometric parameters were assessed in trabecular bone under 20x
magnification using the OsteoMetrics system (OsteoMetrics, Decatur, GA) and classified
under the Turnover, Mineralization and Volume (TMV) system [12]. Normal values for histo-
morphometry were previously obtained from double-tetracycline labeled iliac crest specimens
from 31 pediatric patients with normal kidney function undergoing elective orthopedic surgery
[13].
Immunohistochemistry and Quantification of Bone FGF23, DMP1,
Sclerostin, and Osteopontin Expression
The technique for immunohistochemical detection of protein in bone was adapted from a pre-
viously reported method [14]. In brief, 5 μm sections of bone tissue were de-plastified in xylene
and chloroform, rehydrated in graded alcohol solutions, and partially decalcified in 1% acetic
acid. Endogenous peroxidase activity was quenched in 3% hydrogen peroxide/methanol solu-
tion. Non-specific binding was blocked in avidin-biotin solution and in 5% normal horse
serum with 1% bovine serum albumin. Sections were incubated with affinity purified poly-
clonal goat anti-human FGF23(225–244) (Immutopics Intl, San Clemente, California) (dilu-
tion 1:500), monoclonal anti-human DMP1 (LFMb31)(62–513) (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) (dilution 1:50), monoclonal anti-human sclerostin (R&D Systems,
Minneapolis, MN) (dilution 1:500), or monoclonal osteopontin (LFMb-14) (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA) (dilution 1:500) primary antibody overnight at 4°C in a
humidified chamber. Sections were then incubated with biotinylated anti-goat (Vector, Burlin-
game, CA, USA), anti-mouse (Sigma-Aldrich, St. Louis, MO), or anti-rabbit (Sigma-Aldrich,
St. Louis, MO) antibody; incubated for 30 minutes with StreptABC Complex/HRP kit (Vector)
follow by AEC substract Chromogen (Dako, Carpinteria, CA); and counterstained with Mayer
hematoxilin (Sigma-Aldrich).
For immunohistochemical analysis, iliac crest bone biopsy specimens from 5 adolescent
and young adult subjects with normal renal function were used to represent a population of
healthy controls [6]. Negative controls were performed for each bone section by omitting the
primary antibody. Reproducibility was insured by repeating the immunohistochemistical anal-
ysis on all specimens. FGF23, DMP1, and osteopontin were assessed in the entire area of tra-
becular bone; however, since sclerostin was found to be expressed almost exclusively in the
cortex, its expression was assessed only in cortical bone. Immunoreactivity for FGF23 was
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quantified by counting the number of osteocytes expressing FGF23 in one 5 μm section of tra-
becular bone and normalizing this number by tissue area. Immunoreactivity for DMP1, osteo-
pontin, and sclerostin was quantified using the Ariol scanning system and also normalized by
total (for DMP1 and osteopontin) tissue or cortical (for sclerostin) tissue area. All slides were
scanned at 20x magnification with a red filter and digitized (Applied Imaging Inc., San Jose,
CA). Analyzed fields were manually selected to avoid areas with tissue damage occurring dur-
ing immunostaining. Staining was expressed as pixels/mm2 [15–18]. All analyses were per-
formed with the MultiStain script.
Biochemistry
Blood and urine samples were collected at the time of the bone biopsy. Plasma concentrations
of ionized calcium, phosphate, alkaline phosphatase, and creatinine were determined using
standard methods. In the transplant recipients, glomerular filtration rate (GFR) was measured
by 51-labeled chromium ethylenediaminetetraacetic acid clearance. In the pre-dialysis CKD
population, GFR was estimated using the modified Schwartz equation [19]. In the transplant
recipients, serum concentrations of 25(OH)vitamin D were determined by high performance
liquid chromatography followed by UV detection (HP 1100 Liquid Chromatograph, Agilent
Tech, Santa Clara, CA, USA). Radioimmunoassay was used to determine 25(OH)vitamin D
values in non-transplant CKD patients [20].
Statistical Analysis
Measurements for normally distributed variables are reported as mean ± standard error (SE);
median values and interquartile range are used to describe non-normally distributed variables.
Ranges are presented where noted in the text. The Wilcoxon signed rank test was used to assess
inter-group differences. Relationships between biochemical, bone histomorphometric, and
immunohistochemical parameters were assessed by Spearman correlation coefficients. All sta-
tistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC) and all tests
were two-sided. A probability of type I error less than 5% was considered statistically signifi-
cant and ordinary p values are reported.
Results
Patients and Biochemical Values
Twenty-two pediatric solid organ recipients, all of whom were treated with triple immunosup-
pressant therapy consisting of a calcineurin inhibitor, methylprednisolone, and an antimetabo-
lite, and 12 pediatric pre-dialysis CKD patients were enrolled in the current study. All
transplant recipients received between 400 and 800 IU of vitamin D3 daily; no subjects received
calcitriol or other active vitamin D sterols. As has been previously described, all children had
received glucocorticoids since transplantation and were receiving low dose alternate-day oral
glucocorticoids (methylprednisolone) at the time of biopsy. Cumulative weight-adjusted gluco-
corticoid doses as well as glucocorticoid exposure during the previous 3 years did not differ
between patients with liver or heart and patients with kidney allografts. Other demographic
and biochemical data are displayed in Table 1. In general, patients were within the adolescent
age range and age did not differ between groups. GFR and PTH values did not differ between
kidney transplant recipients and the cohort with pre-dialysis CKD. Serum calcium concentra-
tions were higher while serum phosphorus and alkaline phosphatase values were lower in the
kidney transplant recipients.
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As has been previously reported (Tamminen et al, Pediatric Nephrology 2014), pediatric
transplant patients underwent bone biopsy based on a suspicion of secondary osteoporosis was
based on low areal bone mineral density measured by DXA and/or fracture history. Vertebral
fractures were diagnosed by plain spinal radiographs and loss of vertebral height20% was
used for diagnosis. In the current cohort, which consisted of 22 allograft recipients, 12 (55%) (7
liver, 3 heart, and 2 kidney transplant recipients) had low (<−2.0) lumbar spine BMD Z-score.
Low total hip BMD Z-score was observed in 7 (31%), including 3 kidney and 4 liver allograft
recipients. Four (18%) of the children, all liver allograft recipients, had sustained peripheral
fractures (in humerus, radius, fibula, and metatarsus; 1 in each), whereas vertebral compres-
sions were found in more than half (59%) of all allograft recipients.
To assess the interaction between GFR and transplantation on osteocytic protein expres-
sion, patients with renal allografts were compared to those who were status post other solid
organ transplantation. Overall, GFR was lower and PTH levels were higher in kidney trans-
plant recipients than in recipients of other types of solid organs. However, other biochemical
values did not differ between these two groups of patients.
Bone Histomorphometry
In all three groups of patients, bone volume was within the normal range. Median values for
bone formation rate were also within the normal range; however, values tended to cluster
within the lower end of the normal range. Osteoid accumulation was also in the normal range,
although values for this parameter tended to be in the upper limits of normal. Mineralization
rates, as measured by osteoid maturation time (OMT), were also in the upper range of normal.
With the exception of mineralization lag time, which was slightly higher in kidney transplant
recipients than in the recipients of other solid organ transplants, bone histomorphometric indi-
ces were similar between kidney transplant recipients, recipients of other solid organs, and
non-transplant CKD patients (Table 2).
Table 1. Demographic and biochemical parameters in transplant and CKD patients.
Pre-dialysis, non-transplant
CKD (n = 12)
Kidney transplant
(n = 8)
Liver or Heart Transplant
(n = 14)
Normal
range
Age (y) 13.2 ± 1.4 16.9 ± 2.0 14.8 ± 0.8
Gender 8M/3F 4M/4F 8M/6F
Time since transplantation (y) NA 8.9 ± 2.2 4.8 ± 1.2
GFR (ml/min/1.73m2) 54.7 ± 5.9 42.5 ± 3.8 72.8 ± 4.4 *
Cumulative weight-adjusted glucocorticoid
dose (mg/kg)
NA 53.9 (43.9, 128.4) 82.9(49.9, 110.3)
Weight-adjusted glucocorticoid exposure
(mg/kg/d)
NA 0.05 (0.04, 0.13) 0.12 (0.05, 0.19)
Calcium (mg/dl) *** 9.4 ± 0.1 10.3 + 0.1 ** 10.0 ± 0.1 8.4–10.2
Phosphorus (mg/dl) 4.3 ± 0.3 3.5 ± 0.3 ** 4.0 ± 0.1 2.2–4.7
Alkaline Phosphatase (IU/l) 229 (138, 343) 108 (88, 146) ** 138 (86, 216) 31–103
25(OH)vitamin D (pg/ml) 27 ± 2 31 ± 10 30 ± 3 >30
PTH (pg/ml) 68 (39, 155) 73 (54, 79) 33 (29, 50) * 8–73
* Indicates a difference between kidney transplant recipients and liver or heart transplant recipients (p<0.05)
**Indicates a difference between kidney transplant recipients and pre-dialysis CKD patients (p<0.05)
***Values of transplant recipients converted from mmol/l to mg/dl
doi:10.1371/journal.pone.0138156.t001
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Bone Protein Expression
Bone FGF23 was expressed in cell bodies in discrete clusters of osteocytes at the trabecular
edges and expression of the protein was higher in pre-dialysis non-transplant CKD patients
than in healthy controls (p<0.05 between groups) [6]. Bone FGF23 expression was further
increased in recipients of solid organ transplantation as a whole (p<0.05 from pre-dialysis
CKD patients). Interestingly, although GFR was lower in kidney transplant recipients than in
the recipients of liver and heart allografts, no difference in bone FGF23 expression were
detected between these two groups (Table 3, Figs 1 and 2).
In contrast to FGF23, bone sclerostin expression in controls and in all patients, when pres-
ent, was primarily in cortical bone. Although cortical sclerostin expression correlated with
bone FGF23 expression in all patients (r = 0.38, p<0.05), in contrast to bone FGF23, cortical
sclerostin tended to be lower in non-transplanted CKD patients than in controls (p = 0.056).
However, similar to bone FGF23, cortical sclerostin expression was increased in transplant
recipients as compared to non-transplanted CKD patients (p<0.05). Bone sclerostin expres-
sion did not differ between kidney and liver/heart allograft recipients. Osteopontin was primar-
ily expressed in the matrix of mineralized bone, in lines following cement lines, rather than in
osteocytes themselves. Osteopontin expression was higher in CKD than in transplant recipients
(p<0.01); however, similar to cortical sclerostin expression, osteopontin expression did not dif-
fer between kidney transplant and liver/heart transplant recipients.
DMP1 immunoreactivity was present in osteocyte cell bodies and in dendritic processes
throughout bone. In contrast to FGF23, sclerostin, and osteopontin expression, DMP1 immu-
noreactivity in transplant recipients differed based on organ type received; kidney transplant
recipients had lower DMP1 expression than did their counterparts who had received liver or
heart allografts (p<0.05 between groups). DMP1 expression in liver and heart transplant recip-
ients were similar to values observed in non-transplanted pre-dialysis CKD patients.
Bone FGF23 expression correlated with parameters of skeletal mineralization; osteoid thick-
ness inversely correlated with bone FGF23 expression (r = - 0.46, p<0.01) when all subjects
Table 2. Bone histomorphometric parameters in transplant and CKD patients.
Pre-dialysis, non-transplant CKD
(n = 12)
Kidney transplant
(n = 8)
Liver or Heart Transplant
(n = 14)
Normal range
[13]
Volume
Bone volume (BV/TV) (%) 29.3 ± 2.6 24.8 ± 1.8 21.7 ± 2.2 8.9–34.4
Trabecular thickness (Tb.Th) (um) 132 ± 11 110 ± 8 113 ± 7 91–175
Trabecular separation (um) 324 ± 20 342 ± 31 441 ± 37* 351–737
Mineralization
Osteoid volume (OV/BV) (%) 7.2 ± 3.4 2.2 ± 0.5 2.0 ± 0.3 0.2–5.8
Osteoid surface (OS/BS) (%) 24.8 ± 5.4 16.4 ± 3.4 15.8 ± 2.7 4.3–31.7
Osteoid thickness (O.Th) (um) 11.4 ± 2.5 6.9 ± 0.6 7.0 ± 0.3 2.0–13.2
Osteoid maturation time (OMT) (d) 9 (8, 19) 15 (16, 18) 11 (10, 13) ** 1.2–11.5
Mineralization lag time (MLT) (d) 25 (13, 44) 38 (33, 63) 28 (22, 34) 2.3–63.8
Turnover
Bone formation rate (BFR/BS) (um3/
um2/y)
14.7 (8.7, 28.5) 9.8 (2.8, 18.4) 10.1 (3.5, 26.4) 8.0–73.4
Eroded surface (ES/BS) (%) 6.9 ± 2.0 2.0 ± 0.4 3.1 ± 0.8 0.5–4.3
* Indicates a difference between pre-dialysis CKD patients and liver or heart transplant recipients (p<0.05)
** Indicates a difference between kidney transplant recipients and liver or heart transplant recipients (p<0.05)
doi:10.1371/journal.pone.0138156.t002
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(kidney transplant recipients, liver or heart transplant recipients, and non-transplant CKD
patients) were considered together; similar relationships between osteoid thickness and bone
FGF23 expression were observed when each subgroup was considered individually. No rela-
tionship between bone formation rate and FGF23, DMP1, or sclerostin was observed. No dif-
ferences in expression of FGF23, DMP1, sclerostin, or osteopontin were observed between
transplant patients with clinical fractures (n = 13) and those without (n = 9).
Discussion
The current study demonstrates that therapy with immunosuppressive agents is associated
with an increase in bone FGF23 and sclerostin immunoreactivity, regardless of the type of
Table 3. Protein expression, as determined by immunohistochemistry, in pediatric transplant and CKD patients.
Pre-dialysis, non-transplant
CKD (n = 12)
Kidney transplant
(n = 8)
Liver or Heart Transplant
(n = 14)
Normal range [6]
Bone FGF23/tissue area
(osteocytes/mm2)
0.8 (0.4, 1.2) 1.5 (1.1, 2.8) ** 1.5 (1.1, 2.2)** 0.3 ± 0.1
Bone DMP1/T.Ar (pixels/mm2) 1.06 (0.81, 1.52) 0.68 (0.57, 0.92) 1.09 (0.77, 1.58) * 0.68 ± 0.18
Bone sclerostin/cortical area
(pixels/mm2)
0.9x10-4 (0.4x10-4, 2.2x10-4) 3.9x10-4 (2.5x10-4,
7.6x10-4)**
2.8x10-4 (1.9x10-4, 5.8x10-
4)**
6.7x10-4 (2.2x10-4,
34.5x10-4)
Bone osteopontin (pixels/mm2) 0.052 (0.034, 0.070) 0.038 (0.028, 0.052)** 0.031 (0.024, 0.037)** 0.040 ± 0.009
* Indicates a difference between kidney transplant recipients and liver or heart transplant recipients (p<0.05)
**Indicates a difference between transplant recipients as a group (liver, heart, or kidney) and pre-dialysis CKD patients
doi:10.1371/journal.pone.0138156.t003
Fig 1. Bone (A) FGF23; (B) DMP1 and (C) sclerostin expression in representative samples from a non-
transplant CKD patient, a kidney transplant recipient, and a heart transplant recipient.
doi:10.1371/journal.pone.0138156.g001
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allograft received and despite, in the case of liver and heart allograft recipients, higher GFR.
Bone DMP1 expression, by contrast, appears to be affected by type of solid organ received,
with higher than normal values in liver and heart allograft recipients than in kidney transplant
recipients. Osteopontin expression appears to be lower in transplant recipients than in CKD
patients. An inverse correlation between bone FGF23 expression and osteoid accumulation
(osteoid thickness) was observed in this cohort of patients, similar to the previously reported
relationship between bone FGF23 and histomorphometric parameters of mineralization in
pre-dialysis CKD and dialysis patients [6,7].
While the implications of these findings for bone biology and systemic complications
remain to be evaluated, the current study highlights the importance of transplant status on
bone FGF23 expression. While bone FGF23 has been previously shown to be significantly
increased in pre-transplant CKD patients, this is the first study to examine bone FGF23 expres-
sion in transplant recipients. The overall reason for altered osteocytic protein expression in
CKD in general, and increased osteocytic FGF23 expression, in particular, remains unknown
since these changes occur prior to the development of any detectable abnormalities in circulat-
ing mineral ion or hormone concentrations [21]; however, changes in osteocyte protein expres-
sion suggest that damage occurs to bone that is not detectable by traditional markers of
mineral metabolism or by histomorphometry. In this study, bone from all solid organ allograft
recipients had higher FGF23 expression than did bone from CKD patients. The reason behind
this relationship cannot be fully ascertained from a cross-sectional study; however, glucocorti-
coid therapy has been related to increased circulating FGF23 values in cross-sectional studies
[9] and direct stimulation of osteocytic FGF23 expression by glucocorticoids may partly
explain these increased values. The transplant recipients in the current study, however, also
received treatment with calcineurin inhibitors and antimetabolites which the pre-dialysis CKD
patients did not receive. How these agents may affect osteocytic FGF23 expression is unknown.
Fig 2. Quantification of bone (A) FGF23; (B) DMP1 and (C) sclerostin expression in non-transplant CKD patients, kidney transplant recipients, and
liver or heart transplant recipients. The asterisk represents a difference between allograft recipients and non-transplant CKD patients; the double asterisk
represents a difference between kidney and heart or liver allograft recipients.
doi:10.1371/journal.pone.0138156.g002
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Although immune suppression itself, as noted in the increased osteocytic bone expression
apparent in liver and heart recipients in the current study, appears to increase bone FGF23
expression, decreased GFR does not appear to compound the increased expression associated
with immune suppression. However, although liver transplant and heart transplant recipients
appeared to be the optimal control group to differentiate the relative effects of CKD and
immune suppression on bone FGF23 expression in renal transplant recipients, it is important
to note that these patients also had decreased renal function, with an average GFR of 73 ml/
min/1.73m2. This level of decreased kidney function (CKD stage 2) has been associated with
increases in both circulating FGF23 levels [21] and increased bone FGF23 expression [6]. Since
even mild CKD has been associated with marked increases in bone FGF23 expression, the
increased bone FGF23 expression in the liver and heart transplant recipients may, similar to
the renal transplant recipients, reflect the presence of both CKD and immune suppression. The
implications for this finding are as yet unknown but may potentially include worse cardiovas-
cular prognosis in the setting of immunosuppressive agents.
Data from decades ago suggested a significant presence of mineralization defects in pediatric
kidney transplant recipients [22] and while average and median values for parameters of oste-
oid accumulation and mineralization (i.e. osteoid maturation time and mineralization lag
time) were within the upper limits of normal in the current cohort of transplant recipients, a
significant proportion of the population had values above the normal range [10], despite low-
normal values for bone turnover, suggesting that defects in skeletal mineralization may persist
in the current era of immune suppression. It is important to note, however, that while the pre-
dialysis CKD patients in the current study were recruited from a cross-section of patients for
the research purpose of assessing the spectrum of renal osteodystrophy in the pediatric pre-
dialysis CKD population [11], the transplant recipients were selected for bone biopsy based on
their history of osteoporotic fractures [10]. Whether these selection criteria contributed to
the prevalence of mineralization defects and differences in osteocytic protein expression is
unknown, but osteoporotic fractures are common in prevalent solid-organ transplant recipi-
ents, in whom peripheral fractures occur in as many as 16% and vertebral fractures in 8% [1].
Thus, the solid-organ recipients selected for the current analysis at the very least represent an
important subset of the pediatric transplant population.
Consistent with previous studies [6,23,24], skeletal expression of FGF23 correlated inversely
with osteoid accumulation—most particularly, with osteoid thickness. This suggests that higher
bone FGF23 in transplant recipients may occur in response to glucocorticoid-mediated
changes in bone mineralization, rather than to direct stimulation of osteocytic protein expres-
sion. Although high bone turnover was infrequent in the current cohort of patients, precluding
testing as to whether FGF23, DMP1, and sclerostin are affected by high bone turnover after
solid organ transplantation, no relationship was noted between bone formation rate and
expression of any of the osteocytic proteins, consistent with previous data in pre-dialysis CKD
and dialysis patients [6,23,24]. Although circulating FGF23 were not assessed in the current
study, elevated bone FGF23 expression in recipients of all types of solid organ transplantation
should be considered carefully, particularly in light of the accumulating data suggesting that
elevated FGF23 levels contribute to cardiovascular morbidity [25], to mortality [26], and to
progressive end-organ damage [27].
While DMP1 has been implicated as a down-regulator of FGF23, previous data have sug-
gested that a concomitant upregulation of DMP1 and FGF23 occurs in pediatric CKD, suggest-
ing that DMP1-mediated suppression of FGF23 may be ineffective in this population. In the
current study, bone DMP1 expression was increased from normal controls in pre-dialysis CKD
patients and in liver and heart allograft recipients, although not in kidney transplant recipients.
Whether this finding reflects an interaction between immunosuppressive agents and CKD
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remains to be determined; however, it is interesting to note that serum phosphorus levels were
lower in kidney transplant recipients and phosphorus has been shown to stimulate DMP1
expression [28]. It is also important to note that since the antibody used for immunohisto-
chemical detection of DMP1 in the current study cross reacts with the full-length 98 kDa moi-
ety as well as its fragments [29], increased amounts of total DMP1 in bone may or may not
reflect an increase in its activity.
Expression of sclerostin, an inhibitor of Wnt signaling, has been shown to be increased in
adults with early CKD [7]. In the current study, the decreased sclerostin expression in the non-
transplanted CKD patients as compared to controls may either reflect a difference in osteocyte
biology between children and adults or reflect the fact that PTH values, which are known to
suppress sclerostin, were already mildly increased in this cohort. However, the increase in cor-
tical sclerostin expression in the transplant recipients—even in kidney transplant recipients
with similar circulating PTH values—from the cohort of non-transplanted CKD patients, sug-
gests that immune-suppressive medications act to increase bone sclerostin expression. Interest-
ingly, sclerostin expression did not differ between kidney and other solid-organ allograft
recipients, despite differences in PTH values between these two groups. The implications for
increased bone sclerostin expression post solid-organ transplantation is currently unknown;
however, its role in the inhibition of Wnt signaling, a pathway critical for osteoblast function,
could contribute to the 6-fold higher incidence of all fractures and 160-fold higher incidence of
vertebral fractures in this population than in the general pediatric population at large [1].
Expression of osteopontin, an inhibitor of skeletal mineralization, did not differ between
patients with non-transplant CKD, those status-post kidney transplantation, and those with
heart or liver allografts, suggesting that expression of this specific protein may not be altered by
CKD or by the presence of immune-suppression. Osteopontin was found in the matrix of min-
eralized bone, along cement lines, and while its expression was not related to parameters of
osteoid accumulation on bone biopsy, it is possible that its expression may be related to the
quality and density of mineralized matrix itself, a feature of bone health that is not quantified
by classic histomorphometric analysis but which might be revealed through newer imaging
techniques, including back-scatter electron microscopy or infra-red techniques and which war-
rants further investigation.
In conclusion, the current study demonstrates that solid-organ transplantation and immu-
nosuppressive medication post-transplantation are associated with changes in osteocytic
protein expression, including increased FGF23 and sclerostin expression, that appear to be dis-
tinguishable from the effects of CKD alone on altered osteocyte biology. Although consisting
of a relatively small sample size, the current study presents the first human data on the impact
of immunosuppressive agents on osteocytic protein expression. The impact that these changes
have on skeletal and systemic complications that have been associated with CKD, including
progressive renal dysfunction and cardiovascular disease, is unknown but warrants further
evaluation.
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